Arvinas Reports Q3 2026 Financial Results and Clinical Pipeline Updates
Arvinas (ARVN) reported its third-quarter 2026 financial results, highlighting a significant reduction in operating expenses. Non-GAAP total expenses fell to $53.5 million, a 25% year-over-year decrease driven by disciplined capital allocation and reduced spending in research and development, specifically within the vepdegestrant program. Total revenue for the quarter was $0.5 million, derived entirely from sales-based royalties via an agreement with Rigel Pharmaceuticals. The company maintains a strong liquidity position with $558.9 million in cash and marketable securities, providing a projected runway into the second half of 2028. Looking ahead, Arvinas is focused on several clinical milestones, including upcoming ARV-393 monotherapy data at the ASH Conference in December 2026 and the initiation of Phase I trials for its immuno-oncology degrader, ARV-6723.
Topics: cash runway clinical trials r&d expenses revenue
Read the full article at Motley Fool
Part of the story DeFi Technologies Schedules Shareholder Call for Q3 2026 Financial Results (51 articles)